Arrhythmia Research Technology, Inc. Announces First Quarter

Arrhythmia Research Technology, Inc. Announces First Quarter 2012
Investment in WirelessDx Continues to Impact Operating Results 
FITCHBURG, MA -- (Marketwire) -- 05/17/12 --   Arrhythmia Research
Technology, Inc. (the "Company") (NYSE MKT: HRT) (NYSE Amex: HRT) and
its subsidiaries reported total revenue of $6,305,000 and net loss of
$375,000 for the three months ended March 31, 2012 compared to total
revenue of $6,183,000 and net income of $27,000 for the same quarter
of 2011. Net loss per share for the three months ended March 31, 2012
was $0.13 per share compared to $0.01 in earnings per share for the
same period in 2011.  
James E. Rouse, the Company's President and CEO, commented, "In the
first quarter Micron Products' sensor business had strong sales which
resulted in consolidated revenue being up slightly over the same
period in 2011. Micron's higher sensor volume and silver surcharge
during the first quarter of 2012 were offset by lower sales for
Micron's custom molding and manufacturing division due to the
completion of a defense related product in the first quarter of 2011. 
The net loss of $0.13 per share in the quarter was primarily a result
of the Company's continued investment in WirelessDx, our start-up
medical services subsidiary. R&D expenses related to FDA device
clearance efforts and updates to ART's customizable proprietary
signal-averaging electrocardiography (SAECG) software, PREDICTOR(R),
also contributed to the loss.  
Patient referrals to WirelessDx have increased for the sixth
consecutive quarter. However, expenditures for capital equipment and
scale up in sales and operations personnel continue to significantly
outpace revenues. We expect WirelessDx expenses and capital
expenditures to negatively impact consolidated operating results and
cash through 2012 as marketing and business development efforts
We believe that our continuing focus on growth through business
development programs taking place at our subsidiaries will position
the Company for long term growth." 
About Arrhythmia Research Technology, Inc. 
The Company through its wholly-owned subsidiary, Micron Products,
Inc., manufactures silver plated and non-silver plated conductive
resin sensors and distributes metal snaps used in the manufacture of
disposable ECG, EEG, EMS and TENS electrodes. Micron's MIT division
provides end-to-end product life cycle management through a
comprehensive portfolio of value-added services such as design,
engineering, prototyping, manufacturing, machining, assembly and
packaging. MIT manufactures custom injection molded products for
medical, electronic, industrial and consumer applications, and
provides high end mold design, manufacturing and precision machining
for various industries. The Company's wholly-owned subsidiary,
RMDDxUSA Corp. and its Canadian subsidiary, RMDDx Corporation,
branded "WirelessDx", is dedicated to the development and
commercialization of medical devices and services, medical
information technology, medical diagnostics and remote patient
monitoring through wireless, Internet and telecommunication
technologies. The Company's products also include a customizable
proprietary signal-averaging electrocardiography (SAECG) software
used in the detection of potentially lethal heart arrhythmias and
that is reconfigurable for a variety of hardware platforms. 
For more information please check our websites: 
Forward-looking statements made herein are based on current
expectations of the Company that involve a number of risks and
uncertainties and should not be considered as guarantees of future
performance. The factors that could cause actual results to differ
materially include: our ability to maintain our current pricing model
and/or decrease our cost of sales; our ability to increase sales of
higher margin products and services; variations in the mix of
products and services sold; variability of customer delivery
requirements; ability to market WirelessDx services, manage the
timing of investment in operational infrastructure and ability to
accelerate the pace of revenues from customer implementation; a
stable interest rate market and/or a stable currency rate environment
in the world, and specifically the countries where we are doing
business; continued availability of supplies or materials used in
manufacturing at competitive prices; volatility in commodity and
energy prices and our ability to offset higher costs with price
increases. More information about factors that potentially could
affect the Company's financial results is included in the Company's
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K for the year ended December 31, 2011. 
David A. Garrison
(978) 602-1436
Press spacebar to pause and continue. Press esc to stop.